GYM-329新薬の考察と市場予測 - 2032年

当レポートでは、GYM-329新薬の主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）について調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 FSHDにおけるGYM-329の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 GYM-329市場の評価

• FSHDにおけるGYM-329の市場見通し
• 主要7市場の分析
  • 主要7市場のFSHD向けGYM-329の市場規模
• 市場の分析：国別
  • 米国のFSHD向けGYM-329の市場規模
  • ドイツのFSHD向けGYM-329の市場規模
  • 英国のFSHD向けGYM-329の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: GYM-329, Clinical Trial Description, 2023
• Table 2: GYM-329, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: GYM-329 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: GYM-329 Market Size in the US, in USD million (2019-2032)
• Table 7: GYM-329 Market Size in Germany, in USD million (2019-2032)
• Table 8: GYM-329 Market Size in France, in USD million (2019-2032)
• Table 9: GYM-329 Market Size in Italy, in USD million (2019-2032)
• Table 10: GYM-329 Market Size in Spain, in USD million (2019-2032)
• Table 11: GYM-329 Market Size in the UK, in USD million (2019-2032)
• Table 12: GYM-329 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: GYM-329 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: GYM-329 Market Size in the United States, USD million (2019-2032)
• Figure 3: GYM-329 Market Size in Germany, USD million (2019-2032)
• Figure 4: GYM-329 Market Size in France, USD million (2019-2032)
• Figure 5: GYM-329 Market Size in Italy, USD million (2019-2032)
• Figure 6: GYM-329 Market Size in Spain, USD million (2019-2032)
• Figure 7: GYM-329 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: GYM-329 Market Size in Japan, USD million (2019-2032)

“"GYM-329 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about GYM-329 for Facioscapulohumeral Muscular Dystrophy (FSHD) in the seven major markets. A detailed picture of the GYM-329 for FSHD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the GYM-329 for FSHD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the GYM-329 market forecast analysis for FSHD in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in FSHD.

Drug Summary:

GYM-329 is an investigational anti-myostatin antibody designed to target skeletal muscles, potentially increasing their size and growth. Myostatin is vital in regulating skeletal muscle size by controlling its growth. Inhibiting myostatin may help muscles grow in size and strength. GYM329 has been engineered as a "recycling" and "sweeping" antibody, which means that it may be more efficient at removing myostatin from the blood than a conventional antibody. GYM329 is more targeted and expected to improve the various conditions associated with muscle atrophy and loss of muscular strength.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the GYM-329 description, mechanism of action, dosage and administration, research and development activities in Facioscapulohumeral Muscular Dystrophy (FSHD).
• Elaborated details on GYM-329 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the GYM-329 research and development activities in FSHD across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around GYM-329.
• The report contains forecasted sales of GYM-329 for FSHD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for FSHD.
• The report also features the SWOT analysis with analyst views for GYM-329 in FSHD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GYM-329 Analytical Perspective by DelveInsight

• In-depth GYM-329 Market Assessment

This report provides a detailed market assessment of GYM-329 for Facioscapulohumeral Muscular Dystrophy (FSHD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

• GYM-329 Clinical Assessment

The report provides the clinical trials information of GYM-329 for FSHD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Facioscapulohumeral Muscular Dystrophy (FSHD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GYM-329 dominance.
• Other emerging products for FSHD are expected to give tough market competition to GYM-329 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GYM-329 in FSHD.
• Our in-depth analysis of the forecasted sales data of GYM-329 from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GYM-329 in FSHD.

Key Questions

• What is the product type, route of administration and mechanism of action of GYM-329?
• What is the clinical trial status of the study related to GYM-329 in Facioscapulohumeral Muscular Dystrophy (FSHD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GYM-329 development?
• What are the key designations that have been granted to GYM-329 for FSHD?
• What is the forecasted market scenario of GYM-329 for FSHD?
• What are the forecasted sales of GYM-329 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to GYM-329 for FSHD?
• Which are the late-stage emerging therapies under development for the treatment of FSHD?

Table of Contents

1. Report Introduction

2. GYM-329 Overview in FSHD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. GYM-329 Market Assessment

• 5.1. Market Outlook of GYM-329 in FSHD
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of GYM-329 in the 7MM for FSHD
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of GYM-329 in the United States for FSHD
  • 5.3.2. Market Size of GYM-329 in Germany for FSHD
  • 5.3.3. Market Size of GYM-329 in France for FSHD
  • 5.3.4. Market Size of GYM-329 in Italy for FSHD
  • 5.3.5. Market Size of GYM-329 in Spain for FSHD
  • 5.3.6. Market Size of GYM-329 in the United Kingdom for FSHD
  • 5.3.7. Market Size of GYM-329 in Japan for FSHD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options